Linkedin
RLS logo_header
Linkedin

Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Gen Therapeutic Antibodies

Jingsong Wang, MD, PhD, Founder, Chairman, and CEO of Harbour BioMed, commented: “This strategic collaboration with AstraZeneca marks a significant step in advancing next-generation antibody therapeutics, reinforcing Harbour BioMed’s position as a leader in multi-specific biologics innovation. By leveraging our cutting-edge discovery capabilities and AstraZeneca’s expertise in drug development, we aim to accelerate the creation of transformative therapies for patients with high unmet medical needs.”

Read the full story on "Harbour BioMed Enters into Global Strategic Collaboration with AstraZeneca to Discover and Develop Next-Gen Therapeutic Antibodies"

Share:

More News

FDA Accepts NDA for Giredestrant in ER-Positive Early-Stage Breast Cancer

“Giredestrant represents the first major endocrine therapy advance in early-stage ER-positive breast cancer in decades, where the chance for cure is highest,” said Levi Garraway, M.D., Ph.D., chief medical officer and head of Global Product Development. “The FDA’s filing acceptance brings us closer to delivering a new standard-of-care with the

SOTIO Receives U.S. FDA Orphan Drug Designation for SOT106 for Sarcoma

“Orphan Drug Designation for SOT106 underscores both the urgent need for new treatment options in osteosarcoma and the strength of our ADC platform,” said Radek Spisek, M.D., Ph.D., chief executive officer of SOTIO. “Osteosarcoma is a devastating disease that has seen little therapeutic innovation over the past four decades. Treatment

FDA Granted Fast Track Designation for TER-2013 for HR+ve/HER2neg Breast Cancer

“The designation reinforces the significant unmet need for effective treatment options for patients with advanced breast cancer,” said Charles Baum, M.D., Ph.D., Chief Executive Officer of Terremoto Biosciences. “We are committed to advancing highly selective therapies designed to expand treatment options for patients with difficult to treat cancers.”

FDA Clears amendment to Open U.S. Enrollment in Ongoing Ph 2 THIO-101 Trial Expansion

“Up to five U.S. clinical sites are planned for THIO-101 Parts C and D this year, and we expect to activate a second U.S. site in the coming weeks,” said Vlad Vitoc, M.D., Founder and Chief Executive Officer of MAIA. “To date, data has shown overall survival (OS) beyond two